In addition, the pan-PI3K inhibitor BKM120 showed a potent antitumor ability in both sensitive and MDR breast cancer cells by inhibiting the PI3K/AKT/NF-κB signaling pathway, and the combination of BKM120 with doxorubicin showed a synergistic effect (Hu et al., 2015). This evidence concerns the gene PIK3CB and breast cancer.